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Abstract The OCTN subfamily includes OCTN1, 2, and
3 which are structurally and functionally related. These
transporters are involved in maintenance of the carnitine
homeostasis, which is essential in mammals for fatty acid
b-oxidation, VLDL assembly, post-translational modifica-
tions, and other essential functions. Indeed, defects of these
transporters lead to severe pathologies. OCTN1 and
OCTN2 are expressed in many human tissues, while
OCTN3 gene has been identified only in mouse and rat.
The transporters mediate transport of carnitine and other
substrates with different efficiencies and mechanisms. In
order to over express the three proteins, a screening of
many combinations of E. coli strains with plasmid con-
structs has been conducted. Only Rosetta(DE3) or Roset-
tagami2(DE3) gave significant expression. Higher protein
amounts were firstly obtained with pET-41a(?) or pGEX-
4T1 carrying fusion protein tags which required additional
purification passages. Vectors carrying only a 6His tag,
suitable for single passage purification, were preferred even
though they lead to lower initial expression levels.
Expressions were then increased optimizing several critical
parameters. hOCTN1 was obtained with pH6EX3 in
RosettaGami2(DE3)pLysS. hOCTN2 and mOCTN3 were
obtained using pET-21a(?) in Rosetta(DE3). In particular,
hOCTN2 was expressed only after codon bias, substituting
the second triplet CGG with AAA (R2K mutant). The best
growth conditions for hOCTN1 and mOCTN3 were 28 C
and 6 h of induction, while 4 h of induction for
hOCTN2R2K. The proteins collected in the insoluble
fraction of cell lysates, solubilized with sarkosyl, were
purified by Ni-chelating chromatography. Final yield was
2.0, 3.0, or 3.5 mg/l of cell culture for mOCTN3, hOCTN1,
or hOCTN2R2K. The data indicated that, in spite of the
close evolutionary relations, several factors play different
critical roles in bacterial expression of the three proteins,
thus general criteria cannot be underlined. However, the
strategy of dealing with related proteins revealed to be
finally successful for over expressing all the three sub-
family members.
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Introduction
Not very long ago (70’s) it was believed that many phys-
iological or xenobiotic compounds cross biological mem-
branes by simple diffusion. This assumption has been now
upset. The profound modification of the point of view is a
consequence of the exponential increase of membrane
transporter studies since that time. Indeed, from 70’s the
papers published per year dealing with membrane transport
raised by about four fold to nowadays (results on the basis
of occurrence of ‘‘membrane’’ and ‘‘transport’’ in title field
on http://www.ncbi.nlm.nih.gov/pubmed). It has been thus
assessed that membrane transport systems, with a very
limited number of exceptions, are necessary for uptake,
elimination, and intracellular trafficking of virtually all
nutrients and metabolites, and hence transporters are key
components for maintaining and regulating cell homeo-
stasis. Thus, many of these proteins are essential for life.
Besides the development of methodologies for studying
transport systems, other important achievements stimulated
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the study of membrane transporters especially during the
last two decades: (i) Genome wide sequencing revealed
that genes coding for membrane proteins are much more
abundant than previously thought. As an example, the
genome of H. sapiens contains more than thousand genes
coding for membrane transporters (http://www.membrane
transport.org/) which account for about 3 % of the total
ORFs. (ii) Defects of transporter functions have been cor-
related to several human pathologies of a wide range of
severity [1–6]. (iii) Recently it emerged that transporters
have high relevance in drug delivery, absorption, and side
effect onset representing the first contact point with the
organism [7–9]. However, many structures of bacterial
transporters but no structure of human and very few of
mammalian transporters have been resolved so far (http://
www.membranetransport.org/). This is due to the lack of
methodologies for over expressing and folding membrane
transporters. Indeed, the mitochondrial ADP/ATP trans-
porter, which is a single case of mammalian secondary
active transporter entirely crystallized so far, was obtained
by purification from bovine heart since it is one of the most
abundant mitochondrial proteins [10]. On the basis of the
above considerations, strategies aimed to solve the prob-
lems hampering protein expression and to study structure/
function relationships of transport proteins related to
human pathology are particularly welcome to both trans-
port protein and human health scientific communities.
Problems With Functional and Structural Studies
Methodologies to obtain large amount of folded transport
proteins are essential for studying their structure and
structure/function relationships. Each of the strategies
currently used for producing transport proteins obviously
presents advantages and disadvantages. The features of
each methodology have to be considered as function of
the specific protein and of the studies to be carried out.
This will help the choice of the appropriate experimental
systems. This argument has been previously well
reviewed [11]. In principle, eukaryotic expression systems
would be better for obtaining correctly folded proteins.
However, these systems, with very few exceptions, give
lower yields with respect to bacterial ones. Hence, pro-
teins obtained by expression in eukaryotic organisms are
normally not sufficient for structural studies. Thus, several
efforts are in progress to find suitable conditions for
bacterial expression which remains the method of election
for recovering high amounts of proteins. This system also
allows to perform minimal modification of the proteins,
such as His tag insertion that facilitates the further puri-
fication step, which is also essential for structural and
functional studies.
For its low costs, harmless for humans, fast growth, easy
handiness, and wide empirical experience in its usage,
E. coli is the most used microorganism for protein
expression. However, there are still a lot of unsolved
problems limiting the expression of mammalian membrane
transporters and, in general, of hydrophobic proteins. These
problems are mainly caused by differences in both DNA
composition and protein structure between bacteria and
mammals. E. coli strains have been originally engineered
to improve mammalian protein expression. Examples are
E. coli BL21(DE3) and K-12 from which other optimized
strains were derived [12, 13].
Two clue points in which it can be possible to act for
obtaining increase of heterologous membrane protein
expression are listed below:
Codon Usage and Host Choice
An important challenge for heterologous expression is the
different codon usage of mammals and in particular
humans, which causes difficulties in expressing proteins in
bacteria [14]. For example, E. coli does not use certain
codons (such as AUA for Ile, or AGA and AGG for Arg)
that are frequently used in mammalian genes [15]. This
problem can be at least partially overcome by modifying
the host; accordingly, E. coli strains engineered with tRNA
frequently used in humans, such as Rosetta(DE3) and
BL21-CodonPlus RIL can be employed [12, 13, 15].
Another possibility consists in optimizing the cDNA
encoding the protein of interest according to the general
codon usage of the host and the frequency of codons at 50,
which influence the translation efficiency [14, 16–18].
However, the expression of transport proteins is addi-
tionally hampered by their hydrophobicity, which strongly
compromises expression throughput. Furthermore,
eukaryotic membrane proteins are in average larger than
bacterial counterparts [19] and are characterized by more
complex hydrophilic moieties than the bacterial ones.
Thus, bacterial folding machineries are inefficient for
eukaryotic proteins [20], in particular for mammalian
transporters, originated later in the evolution [21, 22]. It
has been also reported that over expression in E. coli of
eukaryotic membrane proteins results in saturation of the
bacterial Sec translocon, leading to toxicity [20]. Excep-
tions to the higher complexity of eukaryotic proteins are
the mitochondrial transporters which have been the first
over expressed in bacteria [5, 23–25].
Other features of membrane transporters make them
difficult to handle: water insolubility, higher mobility with
respect to water-soluble proteins [26], and the propensity to
form inclusion bodies as a consequence of inter- and intra-
molecular aggregates in the bacteria cytosol. In other cases,
the production of few molecules of heterologous proteins is
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toxic for the microorganisms, causing sudden cell death.
This is the case of several amino acid transporters ([27],
Galluccio and Indiveri unpublished results). E. coli C41,
and C43 strains for toxic protein expression [27] or
Lemo21 which should be effective in membrane protein
expression [28, 29], have been developed from the original
BL21.
In order to overcome problems linked to over expression
of proteins, like membrane transporters, for which a gen-
eral rule seems hard to be pointed out, a system that
bypasses the choice of the appropriate combination host/
plasmid has been established—the cell-free synthesis.
Successful expression of membrane proteins by E. coli
cell-free strategy was recently described [30, 31]. This
system should give the advantages of reducing toxicity of
expressed proteins and easier protein co-expression.
However, in this case also, formation of insoluble aggre-
gates was observed; thus, a modified strategy had been
proposed based on protein translation into detergent
micelles [32]. Eukaryotic in vitro translational systems
from rabbit reticulocyte lysates [33] have also been pointed
out. The main limit of cell-free expression systems, espe-
cially eukaryotic ones, is that even though they could give
fast protein expression, the recovered amount is little, and
normally not enough for structural studies. In few cases,
bacterial cell-free expression led to appreciable results in
terms of protein yield [30].
Another important challenge in protein over expression
is the post-translational modification. Regarding this task,
bacteria cannot perform, as example, the glycosylation of
newborn proteins; however, several reports evidenced that
glycosylation is normally not essential for transport activity
but for other processes such as sorting in eukaryotic cells
([34] and refs herein [35]). Thus, the lack of this modifi-
cation does not compromise functional and structural
studies of transporters. Indeed, the few successfully over-
expressed human (or mammalian) transporters in bacteria
were functionally active [30, 36–39]. However, glycosyl-
ation could be obtained by over-expressing proteins in
eukaryotic cells such as wheat germ extracts [33, 40], yeast
[18] insects cell, such as Sf9 [33, 41]. Even though in these
cases the glycosylation patterns are not always corre-
sponding to those produced by human cells and the amount
of recovered proteins is in general very low.
Plasmid Selection
It is well known that promoter type and strength influence
the levels of protein expression and that fusion tags may
improve solubility of membrane proteins and purification.
On the contrary, in the case of insoluble (membrane)
proteins, high-strength promoter often leads to aggrega-
tion and inclusion body formation. Slowing down the
expression rate in some cases allows membrane protein
expression. Fusion tags are suitable for expression of
hydrophobic proteins. Besides the most known 6, or longer,
His tag, which is used essentially for purification [42],
GST, MBP, NusA, Trx, and SUMO [43, 44] are potentially
useful for improving solubility or even expression yield.
For the expression of membrane proteins a promising
approach might be the fusion with Mistic [45, 46], a small
E. coli outer membrane protein, which can promote the
insertion of the fusion peptide in the E. coli membrane to
help the folding process. Chaperones co-expression has
also been attempted to reduce formation of insoluble
aggregates responsible for protein inactivation and difficult
refolding. Several chaperones are commercially available,
and used either alone or in combination, such as DnaKJE
set or GroEL-GroES [47–49].
None of the above-described strategies revealed itself as
a solution for general purposes of transport protein over
expression. As a consequence, very few eukaryotic plasma
membrane transporters have been heterologously over
expressed so far [30, 36, 37, 39, 50, 51]. This has limited
both the studies of the functional properties and the
determination of the tertiary structures of membrane
transport proteins which only recently started to be solved
[52, 53].
One of the way to face transport protein expression may
consist in dealing with experimental troubles with a group
of proteins linked by common evolution, thus being
structurally and functionally related, and optimize more
than one critical factor among those described in the pre-
vious section. Indeed, related proteins will share similar
responses to changes in protocols of expression and will
have similar solubility properties and folding pathways,
thus giving higher chances of success with at least one of
the family member. Once optimal conditions are set up for
one protein, it should be easier to carry out the expression
of the others by minimal further changes of the experi-
mental conditions. Based on this assumption we have
focused our attention on the OCTN subfamily, which so far
includes three proteins—OCTN1, OCTN2, and OCTN3,
and a hypothetical splice variant OCTN2VT located in ER
instead of plasma membrane [54]. A detailed overview of
the strategies for obtaining these proteins in large amount,
in a pure form, and appropriately folded will be provided,
together with synthetic information on the functional and
on the few structural information available on these
proteins.
Role of the OCTN Subfamily
The OCTN subfamily belongs to the SLC22 family, toge-
ther with OCT and OAT subfamilies and, in the higher
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level of classification, to the Major Facilitator Superfamily
to which more than thousand identified members belong,
accounting for about 25 % of all transporter families [55].
The members of SLC22 family are characterized by
broad substrate specificity: this started evolutionary studies
to understand the origin of such variety. It has been pro-
posed that the SLC22 family has evolved after the diver-
gence of vertebrates and invertebrates [21]. The suggested
mechanism is that of independent tandem duplications
producing gene pairs. Since the duplicated gene products
are functionally alike, gene pairing may be causative of the
broader specificity observed in vertebrates compared to
invertebrates. It has been speculated, furthermore, that the
selective pressure on vertebrates coming from the more
complex surrounding environment, led to a wider speci-
ficity toward several compounds [21].
Function of the OCTN’s Proteins
Since the first identification of the cDNA coding for these
proteins in human and mouse [56–60], it was shown that
besides the structural relationships among the three pro-
teins, a functional link also exists. Thus, the OCTN1-3
proteins are named organic cation transporters novel which
are distinct from the OCTs [21, 59, 61]. The fact that at
least some of the OCTN members recognize carnitine as
substrate indicates that these transporters should be
involved in the maintenance of the carnitine homeostasis in
mammals [61–63]. This molecule does not have a precise
classification since it was considered as vitamin up to the
discovery of its biosynthesis pathway [64]. However, the
biosynthesis does not produce sufficient amount for
the whole body’s requirement; it may be then considered as
a cofactor with, however, imprecise classification. Chem-
ically, carnitine is a zwitterion essential for fatty acid
b-oxidation in mitochondria and peroxisomes, and for
VLDL assembly and protein modification in ER. Indeed,
carnitine acts as shuttle molecule allowing the transfer of
acyl units to CoA for the following oxidation reactions,
while CoA, which cannot cross intracellular membranes,
remains confined in the sub-cellular compartments. More-
over, carnitine is also involved in detoxification from drugs
and xenobiotics since some of these compounds can form
carnitine derivatives such as pivaloyl-carnitine, eliminated
by kidney [62, 63, 65–69]. All these functions are essential
for life, thus the intracellular carnitine concentration
has to be strictly controlled and maintained constant. In
mammals, the carnitine homeostasis is the result of
endogenous synthesis, absorption from dietary source,
renal re-absorption and excretion, distribution to tissues.
This function is realized by a network of transporters and
enzymes which is named carnitine system [63, 70] in which
the three members of the OCTN subfamily very probably
play important roles. In particular, it has been well estab-
lished in several experimental systems that OCTN2 and
OCTN3 accept carnitine as the main substrate while
OCTN1 catalyses carnitine transport at a much lower
efficiency; the OCTN1 and OCTN2 transport systems have
a broad tissue expression demonstrated by RT-PCR anal-
ysis, Western Blot, and immunohistochemistry [56–63 and
references herein]. The carnitine transport mediated by
OCTN1 and OCTN2 has been reported to be dependent on
Na? gradient across plasma membrane, by analyzing the
identified and cloned human and murine isoforms [56–60].
Before over expressing OCTN proteins [39, 50, 51], the
functional and kinetic parameters have been evaluated, in
several experimental models i.e., cell systems, intact brush
border vesicles [56–60, 63, 71], as well as in reconstituted
proteoliposomes [72]. The third member of OCTN sub-
family, OCTN3 has been identified only in mouse and rat;
thus, all the carried out studies concern the murine isoform,
which shares high identity and similarity with the human
OCTN1 and OCNT2 [71] (see Fig. 1; Table 1). In spite of
the still lacking identification of the OCTN3 human gene,
the OCTN3 protein has been detected in human tissues by
western blot and immunohistochemistry using antibody
raised against the murine isoform [71]. OCTN3 is a
membrane transporter with a more narrow tissue expres-
sion profile compared to the other members; it is expressed,
indeed, besides intestine, mainly in testis where it plays an
important role in providing carnitine essential for sperma-
tozoa development [73, 74]; in this district, in fact, its
concentration is much higher than in plasma. The presence
of OCTN3 has been shown also in brain where it may be
involved in carnitine disposition in neurons. In these cells
carnitine taken up by OCTN3 can help detoxification from
drugs [75]. For OCTN1 and OCTN3 sub-cellular local-
izations, mitochondria and peroxisomes have also been
proposed, respectively [76, 77]. Basing on studies con-
ducted in cell systems and in intact vesicles, the carnitine
transport mechanism described for mOCTN3 is pH and
Na?-independent in a uniport mode [59].
The OCTN transporters, furthermore, have been pro-
posed also to recognize and, sometime, transport other
physiological compounds, such as organic cations, as well
as some xenobiotics and drugs [56–61, 78, 79] in line with
the broad substrate specificity mentioned above.
Bacterial Over Expression of the Members
of the OCTN Subfamily
The first step of the study conducted on the OCTN sub-
family proteins consisted in a screening strategy for
checking the expression under different combinations of
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E. coli strains and plasmids constructed with the cDNA
encoding each of the three proteins. As shown in Fig. 2, we
succeeded in finding out some conditions in which each of
the protein was expressed, even though at a low level, i.e.,
\50 % of the maximal expression obtained after optimi-
zation of the growth conditions [39, 50, 51].
Strain–Plasmid Combination
The over-expression studies started from the first OCTN
subfamily member, i.e., hOCTN1, then hOCTN2, and
finally mOCTN3. From Fig. 2 it is evident that the most
critical factor for expression was the choice of appropriate
cell strains. In all cases only two of the tested strains gave
some expression of the three proteins. The combination of
pET-41a(?) or pGEX-4T1 with Rosetta(DE3) or Rosetta-
gami2(DE3) led to the most significant expression of all the
recombinant proteins. As reported in the scientific literature
concerning membrane protein over expression, the pres-
ence of a fusion protein tag should increase the solubility of
hydrophobic proteins. In the case of OCTN subfamily
members we did not observe such effect; in fact the pro-
teins were always present in the insoluble fractions of
induced cell lysates. For hOCTN2, moreover, the plasmid
pE-SUMO revealed to be suitable in over-expressing
SUMOylated hOCTN2 (Fig. 2 and unpublished results).
This result was probably due to a better recognition of the
exogenous mRNA by the translation machinery of the
bacteria.
The presence of the fusion tags had, however, the dis-
advantage of low recovery of protein after purification and
separation procedure, even after optimization. In case of
hOCTN1 a low but significant expression was also
obtained with plasmids not carrying fusion proteins.
pH6EX3 vector, indeed, revealed successful for obtaining a
conspicuous expression of the recombinant protein. This
protein construct contained the small 6His tag suitable for
purifying the transporter. The best expression was obtained
in RosettaGami2(DE3)pLysS, an engineered strain carry-
ing two mutations in cytoplasmic disulfide reduction
pathway to help disulfide bridges formation [50]. This gave
the advantage to form appropriate disulfide(s) in the protein












hOCTN1 85 73 68
hOCTN2 72 85 78 76
Pairwise alignment have been performed by Clustal W. Percent
identity are reported
Fig. 1 Alignment of proteins of the OCTN subfamily. Human
OCTN1, human OCTN2, and mouse OCTN3 were aligned using
the Clustal W software. Identities are indicated by asterisks and
conservative or highly conservative substitutions are indicated by dots
or colons, respectively. The Cys residues, which are conserved, are in
boxes. Transmembrane segments predicted by TM-PRED software
and manually adjusted for the three proteins, are indicated by white
boxes and the corresponding sequences are highlighted in gray
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which revealed to be useful for refolding and functional
reconstitution of the protein. As reported in Fig. 2, the
screening on hOCTN2 and mOCTN3 has been conducted
following the same criteria as for hOCTN1. Thus we have
obtained an acceptable expression, around 30 % of the
maximal, using pET-21a(?) in Rosetta(DE3) cell strain in
case of mOCTN3. This plasmid carries a 6His tag at
the C-ter of the recombinant protein which allowed the
purification procedure on affinity column. Concerning
hOCTN2 fused with GST, it was necessary to grow cells
under osmotic stress conditions to obtain over expression
of the interest protein. However, the highest yield was
reached by applying codon optimization strategy. Based on
the codon preferences of E. coli, the second triplet of
hOCTN2 cDNA, CGG, was substituted with AAA, much
more frequent in E. coli [14]. The AAA codon was chosen
since it led to the conservative substitution R2K and,
hence, very probably will not alter the structure/function
relationship of the protein. The codon bias strategy has
been significantly more successful in terms of protein yield
compared to the one previously described. The modified
cDNA was cloned in the pET-21a(?) and successfully
expressed in Rosetta(DE3)pLysS, yielding hOCTN2R2 K
with C-ter 6His tag, differently from hOCTN1 which had
6His tag at N-ter (not shown in Fig. 2).
Growth and Inducing Conditions Optimization
After choosing the combination plasmid/host, several
parameters influencing the expression were tested and
optimized such as the inducer (IPTG) concentration, the
post-induction temperature, and the growth time. It has
been observed that slower growth, i.e., lower temperature
or low IPTG concentration, led to higher expression, while
faster growth caused lack of expression and/or cell growth
arrest (toxicity) after a certain time. The best condition for
hOCTN1, GST-hOCTN2, and mOCTN3 expression was
obtained at 28 C and 6 h of post-induction growth time
[39, 50], while maximal amount of hOCTN2R2K was
obtained after 4 h of induction [51]. The concentration of
inducer (IPTG) was also optimized for the four constructs.
For hOCTN1 and GST-hOCTN2, the best condition was
0.4 mM IPTG whereas mOCTN3 and hOCTN2R2K nee-
ded reducing the concentration of four folds, i.e., 0.1 mM
IPTG for high-yield expression of protein. In all cases the
proteins were present only in the insoluble fraction of
induced cell lysate. Regarding the growth media used for
the over expression among those tested, the LB medium
was the best choice for hOCTN1, whereas 2X TY was used
in case of hOCTN2R2K and mOCTN3. GST-hOCTN2
needed special growth conditions to recover high yield of
recombinant protein; indeed, it was necessary to subject
cells to an osmotic stress by adding sorbitol and betaine in
the 2X TY medium. The induction of osmotic stress seems
to cause metabolic changes in bacterial cells leading to
better expression of the heterologous protein. In order to
study the function and, if possible, the structure it is
indispensable to obtain purified recombinant proteins.
Then, the following step was the solubilization from pellet.
In this case the three OCTN subfamily members showed
very similar behaviors. Indeed a detergent screening has
been performed in which several molecules were tested in
Fig. 2 Screening of cell strains and plasmids for expression of OCTN
proteins. Tridimensional representation of screening experiments for
a hOCTN1, b hOCTN2, and c mOCTN3, in which different E. coli
strains have been transfected with constructs obtained with each of
the indicated plasmid. Strains are indicated by the commercial names
except for RG2(DE3) which is the abbreviation of RosettaGam-
i2(DE3). The histograms represent the expression level as percent of
the maximal expression obtained for each of the protein [39, 50, 51]
after optimization of all the experimental conditions
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the attempt to find out a non-ionic detergent which is able
to solubilize hOCTN1, hOCTN2R2K, GST-hOCTN2, and
mOCTN3 possibly in native forms, but without any sig-
nificant result. However, these unsuccessful tries gave the
opportunity to partially clean up the cell lysate from the
soluble bacterial proteins which were removed by washing
with non-ionic detergents. The mildest detergent which
was able to solubilize the protein was the ionic sarkosyl.
The minimal solubilizing sarkosyl concentration was 0.8 %
[39, 50, 51].
Purification Procedure and Protein Yield
Assuming that in the solubilized state the three proteins
were unfolded, we searched for a procedure which could
exchange the ionic for a non-ionic detergent. On the basis
of previous experiences described by other groups [80], we
set up a protocol for the purification of the protein
which simultaneously exchanged the detergents. Thus, a
Ni-chelating affinity chromatography was employed where
the protein was tagged with 6His at the N-ter (hOCTN1and
GST-hOCTN2) or C-ter (hOCTN2R2K and mOCTN3)
[39, 50, 51]. After several attempts, a detergent/salts gra-
dient was adopted in the chromatography, which led to
recovery of protein soluble in Triton-X100. This indicated
that some conformational rearrangements had occurred
which most probably rely with the correct folding of the
protein. Evidence for this hypothesis came later, when the
hOCTN1 first and, then, mOCTN3 prepared with this
procedure were successfully reconstituted in active form in
proteoliposomes [38, 39]. The GST fusion in case of
hOCTN2 has also been exploited with the aim of obtaining
a less insoluble proteins which could be purified with an
alternative method to Ni-chelating chromatography.
Unfortunately, this was not the case of hOCNT2 because
the purification yield was very low. Moreover, the GST-
hOCTN2 fusion protein was again recovered in the insol-
uble fraction of cell lysate. The adopted purification
strategies allowed recovery of the proteins with high yields.
The highest amount was obtained for hOCTN2 after codon
bias [51], which drastically increased the yield from a very
low amount of 0.2 mg/l of cell culture with the GST-
OCTN2 fusion protein to 3.5 mg/l of the hOCTN2R2K
[51]. The low yield of purified hOCTN2 from GST-
hOCTN2 was mainly due to the additional step of
purification on size exclusion chromatography with
Sephadex G-200 resin after thrombin cleavage of GST
from hOCTN2. The yield of hOCTN1 was 3.0 mg/liter,
while the yield of mOCTN3 was slightly lower than the
other two members, i.e., 2.0 mg/l [39]. Taken together, all
these data indicated that there are no straightforward cri-
teria for improving the yield of even closely related pro-
teins when expressing them in bacteria. Several critical and
unidentifiable factors probably play roles in the interaction
and processing of the mRNA/protein by the bacterial
translation machinery. Indeed, in the case of hOCTN2 the
simple change of the second codon revealed as deus ex
machina to obtain over expression.
Apparent Molecular Mass of the Three Proteins
and Relationships With the Structure (Sequence)
After purification, the three proteins were analyzed on
SDS-PAGE. Immunodecoration using anti His-antibody was
also employed to confirm the identification. Patterns on
SDS-PAGE of the purified 6His-hOCTN1, hOCTN2-R2K-
6His, and 6His-mOCTN3 showed that the apparent molec-
ular masses of the three proteins were always about 10 kDa
lower than the respective calculated masses [39, 50, 51] and
slightly different among each other. This phenomenon has
been already reported as a common feature of membrane
proteins as ‘‘gel shifting’’ [80, 81]. These differences could
not be easily explained on the basis of the physicochemical
properties of the proteins especially in the light of the finding
that single substitution in hydrophobic proteins causes strong
variations of migration on SDS-PAGE [81]. Indeed, both the
pI and the calculated molecular mass are not in line with the
slightly different apparent molecular mass on SDS-PAGE of
the three proteins (Table 2). mOCTN3 has an apparent
smaller molecular mass with respect to OCTN1 and OCTN2
than expected from the very low difference of about 1 kDa in
the theoretical mass. Thus, other factors should be involved
in the migration shifts. Besides the high hydrophobicity of
the proteins, it can be hypothesized that the observed general
faster migration could be attributed to a compaction caused
by formation of disulfides. The three OCTNs have, indeed, in
their primary structure seven Cys residues which can form
inter- and intramolecular disulfides. In previous reports ([81]
and references herein) it has been shown that disul-
fides reduce SDS binding to globular proteins as well as
Table 2 Physicochemical
properties of the members of the
OCTN subfamily
Data have been obtained with
pI/pMW tool at the web site
http://www.expasy.org
hOCTN1 hOCTN2 6His-mOCTN3 mOCTN3-6His
pI 7.11 7.66 8.32 8.51
Theoretical MW (kDa) 64.5 63.8 64.4 65.7
Apparent MW (kDa) 54 54 52 53
Hydrophobicity (%) 53 52 48 41
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membrane proteins and have been linked to a faster migra-
tion of oxidized forms compared to the reduced ones. In
particular this has been demonstrated for hOCTN1. The
treatment of the protein with 1 M b-mercaptoethanol,
indeed, led to increase of the apparent molecular mass on
SDS-PAGE up to the theoretical one [50]. The formation of
disulfides in hOCTN1 may occur, mainly, among the three
Cys residues located in three adjacent transmembrane seg-
ments, i.e., in a microenvironment less available for weaker
reducing agent. Moreover, it is plausible that disulfide for-
mation is important for the secondary structures maintenance
which, on the other way round, hides the disulfide(s) itself.
The smeared migration on SDS-PAGE of the over-expressed
mOCTN3 could be still ascribed to different redox states of
the protein [39]. Moreover, whether the redox status may or
may not be related to the function of the proteins needs to be
better investigated. On the other hand, the little variations of
migration among the three proteins could be attributed to
differences in the primary structure. A previously proposed
hypothesis [81] is that more hydrophobic mutants generally
bind more SDS leading to reduced gel mobility. This
observation could be valid also for the three OCTN sub-
family members since hOCTN1 shows a higher hydropho-
bicity with respect to the other two members (see Table 2).
From the multi-alignment analysis depicted in Fig. 1 and
from the data in Table 2, it can be observed that the percent in
transmembrane segments is little different among the three
proteins as well as the variations of charges in the non-
conserved regions. These little differences might be deter-
minant of the small mobility variations.
Perspectives
Functional Analysis and Relevance for Human Health
Notwithstanding the great number of publications dealing
with OCTN subfamily members, their functions are still
not completely understood. Even though OCTN’s are quite
ubiquitously expressed and are described as plasma
membrane proteins, in some reports different cellular and
sub-cellular localizations have been shown. These dis-
crepancies could also be explained by the existence of
alternative splicing of the coding genes as previously
suggested in evolutionary analysis [21]. In particular, for
OCTN2 an alternative splice form has been described with
different cellular localization and possible functions; it
seems, in fact, that this isoform with an insertion of 24
amino acids does not transport carnitine [54].
The strategies described in this review revealed as a useful
tool for over expressing the mammalian isoforms of OCTN
subfamily members. The purified proteins, being soluble in
the non-ionic detergent Triton X-100, could be used for both
functional and structural studies upon recovery with high
yield. This mild and non-denaturing condition results in a
native form of the protein, suitable for further analysis. In this
respect, it has to be highlighted that some functional studies
have already been performed on purified hOCTN1 and
mOCTN3 using liposomes to reconstitute the transport
activity. The proteoliposome tool gives the advantage of
studying the purified transporters in the absence of other
transport proteins or enzymes otherwise present in cell sys-
tems. hOCTN1 was one of the first plasma membrane protein
heterologously expressed to be reconstituted in liposomes
[38]; the ability of the recombinant hOCTN1 to transport
tetraethylammonium (TEA) and, with lower affinity, carnitine
and ergothioneine has been shown. The transport was clearly
inhibited by several organic cations and substrate analogs
[38]. Noteworthy acetylcholine has been assessed to be a
substrate of hOCTN1. The characteristics of the acetylcholine
transport [82, 83] pointed out a new potential role of hOCTN1
in the non-neuronal cholinergic system, shedding new light on
the potential pathophysiological role of OCTN1. Moreover,
by this experimental approach some chemicals, reacting with
Cys residues, have been evaluated for their inhibitory prop-
erties. It has been shown that almost all of them, in fact, are
able to interact with the transporter, blocking substrate bind-
ing or transport reaction. This is in line with the presence of
seven Cys residues in the primary structure of the transporter
which might be able to interact with the compounds. These
Cys are highly conserved (Fig. 1) among the OCTN sub-
family members demonstrating their importance in main-
taining the tertiary structure and the transport mechanisms.
This is in line with the fact that Cys is one of the ‘‘gainer’’
amino acid, i.e., is one of the amino acids that increased along
evolution of the protein [20]. hOCTN1 transport is regulated
by physiological monovalent cations such as Na? or K?. In
the presence of extracellular Na?, hOCTN1 mainly catalyses
acetylcholine efflux [83]. The reconstitution in liposome has
also been used to study the recombinant mOCTN3 over
expressed in E. coli [39]. Several data regarding the function
of mOCTN3 previously studied in cell systems have been
confirmed. Some new properties have been described such as,
the inhibition by c-butyrobetaine, precursor in the biosyn-
thetic pathway of carnitine. This may play a role in regulating
carnitine transport via mOCTN3. On a physiological point of
view, mOCTN3 has been suggested to play a role in the car-
nitine network together with OCTN2 and, at lower extent,
OCTN1 [63].
This system is essential for regulation of homeostasis
particularly for those living organisms, like humans, in
which more than half of the body’s carnitine is supplied by
the diet [63, 68, 84, 85]. It is, then, not difficult to imagine
that alterations of the carnitine homeostasis is responsible
for a plethora of pathological states which range from
severe syndromes caused by gene defects of transporters
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[2, 84] to light phenomena such as side effects of drugs
which interfere with transporters [61, 63, 78, 86–88].
Among inherited alterations, some point mutations on
OCTN2 coding gene have been clearly related to primary
carnitine deficiency [OMIM 212140; 2, 86, 89, 90]; this is a
recessively inherited disorder of fatty acid oxidation char-
acterized by hypoketotic hypoglycemia, and skeletal and
cardiac myopathy. The majority of natural mutations
identified introduce a premature stop codon or impair
insertion of the mutated transporter in plasma membrane;
other missense mutations are responsible for a strong
decrease in carnitine uptake due to change in transporter
affinity toward the molecule or insensitivity to sodium
stimulation, OCTN2 being a Na?-dependent transporter
[86, 89, 90]. It has also been reported that some OCTN2
gene mutations are related to sudden infant death syndrome
[91] with a specific cardiac and hepatic histopathology.
OCTN1 is the less effective in carnitine transport among
OCTN subfamily members and is involved in acetylcholine
transport [82, 83]. However, genetic alterations of both
OCTN2 and OCTN1 coding genes are associated with the
onset of inflammatory bowel diseases (IBDs), such as
Crohn’s disease [92], which are becoming more and more
interesting in terms of development of possible treatments,
since chronic inflammation may play a role in the patho-
genesis of sporadic colorectal cancer. Moreover, it is
known that OCTN1 polymorphisms may help to predict
malignant progression of IBD [93, 94]. Acetylcholine has
been shown to play a role in inflammatory processes [95];
thus transport of acetylcholine in a non nervous tissue, like
intestine, is a new field of investigation. The third member
of OCTN subfamily, even if OCTN3 has not yet been
genetically identified in human genome, has been associ-
ated with male infertility in rat and in mice at different
degrees of severity ranging from oligospermia to aspermia
[75, 76, 96, 97], being mainly expressed in testis, besides
intestine like OCTN1 and 2. Indeed, the carnitine con-
centration in epididymis is much higher (up to 2000 folds)
[63] than in plasma suggesting that any alterations of car-
nitine transport in testis might be causative of homeostasis
derangement. The carnitine homeostasis and its derange-
ment is important also in cancer, since cancer cells show
great metabolic changes, shifting from aerobic to anaerobic
ATP production bypassing the mitochondrial function. In
this scenario, carnitine has been suggested to play a regu-
latory function in the metabolic switch observed in cancer
[63] and, thus, plasma carnitine transporters might be
altered in their function or expression. Down regulation of
OCTN2 in several epithelial cancers has been shown [98].
The fact that OCTNs are also expressed in brain where the
transport mechanism of carnitine and its derivatives (with
drugs as example) is not completely understood and
definitively clarified is of great interest. Furthermore on a
pathophysiological point of view, it is noteworthy that
OCTN subfamily members have also been shown to
interact and, sometimes, to transport [61, 78, 79, 87] a wide
spectrum of xenobiotics, including drugs causing a reduc-
tion of carnitine or TEA transport. Some of these drugs
may have inhibitory effect on substrate recognition and
transport by the OCTN subfamily members, being a cause
of slight alteration of carnitine metabolism in whole body,
explaining some of the side effects of drugs; in some cases,
in fact, those side effects mimic, in a milder form, the
symptoms of primary carnitine deficiency [88–90]. These
interactions in some cases may be due to disulfides for-
mation between the compounds and Cys residues of the
protein. In this respect, the generation of site-directed
mutants of hOCTN1, hOCTN2, and mOCTN3 is important
to understand the role of the single cysteine in transport
mechanisms or regulations by chemicals.
The over expression in heterologous system followed by
purification and reconstitution in liposomes can represent a
good experimental tool for better understanding the func-
tional properties of the natural mutants of OCTNs for
which a clear association to human pathologies exists.
Impaired acetylcholine efflux has been observed in the
L503F mutant of hOCTN1 which is associated to Crohn’s
disease [82]. The same strategy will allow functional and
kinetic characterization of the OCTNs splicing variants; as
suggested above some of these variants may have a dif-
ferent sub-cellular localization and/or function or may have
tissue-specific distribution.
Structural Analysis
The intrinsic flexibility together with the hydrophobicity of
membrane transporters make them a great challenge for
structural analysis. In fact despite the availability of
advanced technologies for attempting such studies, there is
currently a large imbalance between the number of solved
tridimensional structures of soluble enzymes and that of
membrane proteins; if we straiten the analysis to mam-
malian membrane transporters, the number of structures
decreases dramatically. The structural studies need high
amount of purified proteins and this, for membrane trans-
porters, still represents a big limit. The purified protein
recovered in high yield could be used for solving tridi-
mensional studies. Hereto just bidimensional topological
models have been proposed [63, 82]; a topology with 12
transmembrane helices has been predicted for the OCTN
subfamily members (see Fig. 1). A big extracellular loop
exists between the first and the second helix with potential
glycosylation sites (three conserved Asn residues) and four
Cys residues, which is supposed to be the most reactive
with SH-reacting xenobiotics since it is the most exposed
toward extracellular environment (Figs. 1, 3). The primary
732 Mol Biotechnol (2013) 54:724–736
123
structure of this loop is quite well conserved among the
three OCTNs. Moreover, according to these models, the
N- and C-ter of the proteins as well a second loop, which is
less conserved, between sixth and seventh transmembrane
helix (Fig. 3) are intracellularly exposed [50, 63, 82]. The
alignment in Fig. 1 shows that at this level hOCTN1 and
hOCTN2 are more similar to each other than to mOCTN3.
This could be explained by species-specific differences and
by the fact that the second loop could be a potential site of
intracellular regulatory pathways more or less active in
humans or in mice. Some help in studying the transporter
structure is given by homology modeling using, as tem-
plate, known structures of other proteins. This has been
previously done, as example, for rOCTs using the tertiary
structure of Lac permease of E. coli as template [61]. Even
though OCTs and OCTNs share some similarities, the
tertiary structures of OCTN cannot be easily designed on
Lac permease-deposited model essentially due to the dif-
ference in the large hydrophilic loop which is not present in
Lac permease (http://www.rcsb.org/pdb). Among the sec-
ondary active transporter for which a structure in PDB
bank has been recorded, there is the carnitine transporter
CaiT from E. coli which catalyses exchange of L-carnitine
with c-butyrobetaine across E. coli membrane [99]. How-
ever, it was not possible to use this structure to model
OCTNs, because the sequences of the transporters are too
different. All together, this information shows the limits in
solving tertiary structure of membrane transporters. It is
plausible to believe that as for the over-expression strate-
gies, attempting crystallization of proteins belonging to the
same subfamily could also be helpful in finding successful
methods.
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